Anlotinib enhances the antitumor immunity of radiotherapy by activating cgas/sting in non-small cell lung cancer

HIGHLIGHTS

• who: Dong Han from the In vivo mouse models All studies were supervised and approved by the Ethics Committee of Tianjin Medical University Cancer Hospital and InstituteAll mice were purchased from SiPeiFu (Beijing, China) and maintained under specific pathogen-free conditions. have published the research: Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer, in the Journal: (JOURNAL) of 28/06/2022
• what: In the current study, only tumor growth was delayed and exhausted T_cells decreased in the radioimmunotherapy group compared to IR alone, whereas CD8+ T_cell . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.